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Abstract 
Background: The prevalence of papillary thyroid microcarcinoma (PTMC) is continuously increasing but its clinical 
significance and management is still debatable. The aim of this study was to investigate possible changes in the clini-
cal presentation, tumor characteristics, treatment modalities and long-term outcome during the last three decades in 
patients with PTMC.
Methods: We studied 335 patients with PTMC who were followed up for at least 5 years, from 1982 to 2015, and 
treated in accordance with the current literature or guidelines at each time-period. Patients were classified according 
to year of diagnosis into two time periods, TP1 from 1982–2000 and TP2 from 2001–2010.
Results: The mean follow-up of the whole cohort was 10.6 ± 5.3 (median 9) years. No change was noted in the 
mean age at diagnosis or the female to male ratio during the two time periods. In regard to tumor characteristics, 
multifocality and non-encapsulated follicular variant of PTMC was more often present while classic PTMC was less 
common in patients in the TP2, compared to patients in the TP1 (p = 0.007, p < 0.001 and p = 0.043 respectively). 
The prevalence of incidental PTMC was high but similar in both time periods (84.6 vs 80 %, p = 0.286). The majority of 
patients in TP2 underwent a total or near total thyroidectomy compared to patients in TP1 (91.7 vs 80 %, p = 0.001). 
However, more patients underwent thyroidectomy for toxic multinodular disease and less for Graves’ disease during 
TP1 compared to patients in the TP2 (p = 0.02 and 0.043 respectively). A significant percentage of patients underwent 
adjuvant radioiodine ablation, yet no difference was found between the two time periods (73.8 vs 79.5 %, p = 0.228). 
The rate of persistence was very low and not significant (3.1 vs 6.6 %, p = 0.165), while disease recurrence was 
observed in only 2 (0.6 %) patients, one from each time period.
Conclusions: We did not observe any important changes regarding the clinical presentation or tumor characteristics 
of PTMCs during a 30-year period. With applied interventions a favorable course was confirmed in the majority of 
patients without differences in recurrence or persistence during the last three decades.
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Background
During the last decades, papillary thyroid cancer (PTC) 
has shown the largest increase in incidence amongst all 
human solid cancers worldwide [1–4]. This increase 
is mostly the result of identification of smaller thyroid 
tumors due to the routine use of high-resolution thy-
roid ultrasonography (US) and imaging for non-thyroid 
related conditions, as well as the application of total or 
near total thyroidectomy in surgery [5, 6].
Papillary thyroid carcinomas equal to or less than 
1 cm are classified as papillary thyroid microcarcinomas 
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(PTMCs) [7]. According to autopsy studies they seem to 
be frequent and often unnoticed during the entire lifes-
pan [3, 4]. Since PTC presents itself an overall excellent 
prognosis with a 5-year survival of 97 % [8, 9] aggressive 
management of such small thyroid malignancies is rather 
debatable. In fact recent guidelines based mainly on retro-
spective studies recommend a non-aggressive treatment 
for PTMC similar to that of any other benign thyroid nod-
ule and highlight no need for completion thyroidectomy, 
prophylactic lymph node dissection, radioiodine ablation 
and suppressive thyroxine treatment [10, 11].
On the other hand, several studies have identified 
lymph node metastases at presentation, loco-regional 
recurrences during follow-up and rarely distant metas-
tases and even cancer-related deaths. These latter studies 
report several risk factors for recurrence and emphasize 
both the importance of early identification of PTMCs and 
their aggressive management as in non-PTMCs [12–18]. 
However, most studies on PTMCs have a relatively short 
follow-up. As recurrences may occur later it is obvious 
that there is a need for longer follow-up studies. In the 
present study we retrospectively investigated the out-
come of 335 patients with PTMCs followed up regularly 
for a minimum of 5 years and up to 33 years. Moreover 
we investigated possible changes in the clinical presen-
tation, tumor characteristics and outcome of PTMCs 
presented during a 30-year time period in Greece per-
forming a comparison between earlier and more recent 
decades.
Methods
During a 30-year time period, from 1982 to 2010, a 
total number of 523 patients with PTMC attended the 
Departments of Endocrinology, Diabetes & Metabolism 
at “Evangelismos” Hospital, the Hellenic Red Cross Hos-
pital and “Amalia Fleming” Hospital in Athens, Greece. 
Of them, 335 patients have been followed up for at least 
5 years and were included in the study.
Research has been approved by the Ethics Committees 
of the “Evangelismos” Hospital, Hellenic Red Cross Hos-
pital and “Amalia Fleming” Hospital in Athens, Greece 
and all clinical investigations have been conducted 
according to the principles expressed in the declaration 
of Helsinki.
In order to examine possible changes in the clinical 
presentation, tumor characteristics, treatment modali-
ties and long-term outcome, patients were divided into 
two time periods from 1982–2000 and from 2001–
2010. Division was based upon the year of diagnosis 
and change in patients’ approach with the introduction 
of recombinant TSH in the follow-up of low risk PTC 
[8]. Written informed consent was obtained from all 
participants.
Routine use of thyroid ultrasonography (US) was estab-
lished in Greece since 1995 and 48/130 (36.9 %) patients 
underwent this examination during the first time period, 
while 205/205 (100  %) patients during the second time 
period. Regarding fine-needle aspiration, its routine use 
was established in Greece since 1999 and 38/130 (29.2 %) 
patients underwent pre-operatively this examination dur-
ing the first period, while 156/205 (76.1 %) patients dur-
ing the second time period. Radioisotope scan prior to 
surgery was performed in 19/130 (14.6 %) patients dur-
ing the first time period, while in 15/205 (7.3 %) patients 
during the second time period. The surgical policy of our 
endocrine departments was lobectomy for toxic adeno-
mas and total or near total thyroidectomy for the rest 
cases. The pathological examination of the thyroid speci-
mens was based on the criteria of gross examination that 
have been established by Nikiforov [19]. The pathological 
blocks were corresponded one in every 5  gr of the thy-
roid specimens.
Follow up was conducted at 6–12  months after initial 
treatment and yearly thereafter or more often, depending 
on the clinical course. At each visit, all patients underwent 
physical examination, imaging studies (cervical ultra-
sonography or I131 whole body scan) and measurement of 
serum thyroglobulin levels with concurrent thyroglobulin 
antibodies assessment, off-thyroxine therapy. From 2001 
onwards, assessment of disease outcome was mainly per-
formed with cervical ultrasonography and thyroglobulin 
stimulation with recombinant human thyrotropin (Thyro-
gen, Genzyme Copr., Cambridge, MA) [10, 11].
Thyroglobulin was measured with an IRMA method 
(Sorin, Biomedica Saluggia, Italy) with a detection 
limit of 3  mg/l, which from July 1995 was modified to 
1  mg/l. Patients with elevated basal thyroglobulin levels 
(>3 mg/l until 1995 and >1 mg/l thereafter) or stimulated 
(>3 mg/l after 2001) were classified as having persistent 
or recurrent disease even if other tests (including whole 
body scan) were negative, as previously described [20]. 
However thyroglobulin values just over the detection 
limit were not considered as indicative for active dis-
ease, unless confirmed at the same time by imaging or 
biopsy or by a repeatedly elevated thyroglobulin value. 
Thyroglobulin values were not used in the follow up of 
patients with positive thyroglobulin antibodies. TSH 
was measured with IRMA (International CIS, Gif-sur-
Yvette, France) during 1980s and sensitive IRMA method 
(Henning, Berlin, GMBH) with analytical sensitivity of 
0.03 mU/ml, thereafter.
New evidence of disease occurring more than 1  year 
after initial diagnosis was classified as cancer recurrence. 
Cancer was classified as persistent if residual invasive or 
metastatic disease persisted despite therapeutic interven-
tions more than 1 year after initial diagnosis.
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Statistical analysis
Results are presented as mean  ±  SD for continuous 
variables and as absolute numbers or percentages for 
categorical variables. Distribution of continuous param-
eters was tested by Kolmogorov–Smirnov Test. Dif-
ferences in continuous variables between groups were 
tested using Independent T Test or Mann–Whitney U 
Test, as appropriate. Differences in categorical variables 
between groups were tested using χ2 test with Yates cor-
rection and Fisher’s exact test when needed. All statistical 
analyses were performed using the Statistical Package for 
Social Sciences (SPSS 16.0, Inc, Chicago, IL, USA). A p 
value of < 0.05 was considered statistically significant.
Results
The clinical and histopathological characteristics of the 
whole cohort are presented in Table 1.
Patients were followed up for 10.6  ±  5.3 (median 9, 
range 5–33) years. Mean age at diagnosis was 48.9 ± 12.6 
(range 16–81) years and the majority of them were 
females (264, 78.8 %).
Two hundred ninety two (87.2 %) patients underwent a 
total or near total thyroidectomy (24 h uptake <5 %) and 
43 (12.8 %) patients an incomplete thyroidectomy (24 h 
uptake >5 %) of whom 13 were submitted to further com-
pletion surgery. Hyperthyroidism was present at diag-
nosis in 46 (13.7 %) of these patients, of whom 21 were 
diagnosed with Graves’ disease. In 47 patients (14  %) 
autoimmune thyroiditis was present. Family history 
was positive only in five patients (1.5  %). Eighty-seven 
patients (26  %) presented with single nodular and 248 
(74 %) with multinodular disease. From the patients who 
presented with a single nodule, 26 of them had a FNA/
LN positive, 15 had hyperthyroidism (five with Graves’ 
disease and 10 with Toxic Adenoma) and the remaining 
36 had an incidental PTMC inside a prominent benign 
nodule.
PTMC was discovered incidentally in 274 (81.8  %) 
patients undergoing surgery for other pathology non-
related to thyroid malignancy, while 61 (18.2 %) patients 
were operated for suspicious FNA or positive lymph 
nodes. Unifocal PTMC was detected in 215 (64.2  %) 
patients with 109 of them (50.7  %) having a focus of 
1–5  mm and the remaining 106 (49.3  %) a focus of 
6-10 mm. Multifocal disease was detected in 120 (35.8 %) 
patients. None of these patients had distant metasta-
ses. However loco-regional extension and lymph-node 
involvement (T  >  1 and/or N  >  0) were detected in 36 
patients (10.7  %); 22 with unifocal and 14 with mul-
tifocal disease (p  >  0.05). Of these 22 cases with unifo-
cal disease and loco-regional extension/lymph-node 
involvement, 10 had a lesion of 1-5 mm and 12 a lesion 
of 6-10 mm (p > 0.05). Capsule involvement was present 
in 68 (20.3 %) of whom 43 had unifocal and 25 multifo-
cal disease (p > 0.05). Amongst the 43 patients with uni-
focal disease and capsule involvement 12 had a lesion of 
1–5 mm and 31 a lesion of 6–10 mm (p < 0.001).
The histological subtypes of PTMC were as follows: 170 
(50.7 %) classic papillary (CPC), 61 (18.2 %) encapsulated 
follicular variant (EFVC), 58 (17.3  %) non-encapsulated 
follicular variant (N-EFVC), 41 (12.3  %) sclerosing vari-
ant (SVC) and 5 (1.5 %) tall-cell variant (T-CVC).
Two hundred fifty nine (77.3 %) patients of the whole 
cohort underwent adjuvant radioiodine ablation due to 
worrisome histologic subtypes, multifocal disease, thy-
roid capsule invasion, lymph node involvement or thy-
roid remnants. The mean follow-up of the whole cohort 
was 10.6 ± 5.3 (median 9, range 5–33) years. During fol-
low up disease recurrence was observed in only 2 (0.6 %) 
Table 1 Clinical and histopathological characteristics of the 
whole cohort
CPC classic papillary, EFVC encapsulated follicular variant, N-EFVC non-
encapsulated follicular variant, SVC sclerosing variant, T-CVC tall-cell variant
Number of patients 335
Age at diagnosis 48.9 ± 12.6 (range 16–81) years
Gender 264F (78.8 %)
71 M (21.2 %)
Hyperthyroidism 46/335 (13.7 %)
Graves 21/46 (45.7 %)
Hashimoto 47/335 (14 %)
Family history 5/335 (1.5 %)
Singlenodular 87/335 (26 %)
Multinodular 248/335 (74 %)
Incidental 274 (81.8 %)
Non-incidental 61 (18.2 %)
Unifocal 215/335 (64.2 %)
Multifocal 120/335 (35.8 %)
<or = 5 mm 109/215 (50.7 %)
>5 mm (of unifocal cases) 106/215 (49.3 %)
Metastases 0/335 (0 %)
Capsule involvement 68/335 (20.3 %)
T > 1 and/or N > 0 36/335 (10.7 %)
Histological types 170/335 (50.7 %) CPC
61/335 (18.2 %) EFVC
58/335 (17.3 %) N-EFVC
41/335 (12.3 %) SVC
5/335 (1.5 %) T-CVC
Total or near total thyroidectomy 292/335 (87.2 %)
I131 259/335 (77.3 %)
Follow up 10.6 ± 5.3 (median 9, range 5–33) 
years
Recurrence 2/335 (0.6 %)
Persistence 13/335 (3.9 %)
Disease free 320/335 (95.5 %)
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patients, six and 20  years after initial diagnosis and 
remission. Both of them had an incidental PTMC, classi-
fied as T1N0 and a negative family history. One of them 
had undergone adjuvant radioiodine ablation. The recur-
rence was in the thyroid bed alone.
Thirteen of 335 (3.9 %) patients had persistent disease 
at the end of the follow up. The mean age at diagnosis of 
these patients was 55.3 ±  14.2 (range 37–81) years and 
seven of them were men. Four of them presented with 
hyperthyroidism, three of whom had Graves’ disease. 
One had Hashimoto disease. None of them had a posi-
tive family history. Only one presented with a single nod-
ule. Five of them underwent surgery for suspicious FNA 
or positive lymph nodes and in the other eight patients 
PTMC was discovered incidentally. Seven of these 13 
patients had unifocal disease of whom only two had 
a focus greater than 5  mm. Capsule involvement was 
present in three of these patients, 1 of them was T  >  1 
and five of them N  >  0 (4 CPC, 1 SVC). The histologi-
cal subtypes in these patients were: 10 CPC, 2 SVC and 
1 N-EFVC. All these 13 patients underwent thyroid rem-
nant ablation and 8 of them received further radioiodine 
therapy (250–420 mCi). The remaining five patients did 
not undergo further radioiodine treatment due to dif-
ferent causes (three lost to follow-up, one with relapsing 
chronic pancreatitis and one unwilling to stay in the spe-
cial room).
We found no statistically significant difference in per-
sistence (0.4 vs 1.3  %, p  =  0.354) or recurrence (3.1 vs 
6.6 %, p = 0.165) events between the radioiodine ablated 
and non-ablated patients, respectively. The remaining 
320/335 (95.5 %) patients were free of disease.
Comparison between PTMC patients presented into two 
time periods
Patients were classified into two time-period groups 
according to the year of diagnosis: time period 1, 1982–
2000 (n = 130) and time period 2, 2001–2010 (n = 205). 
Comparisons of clinical and histopathological character-
istics between the two groups are presented in Table 2.
No change was noted in the mean age at diagnosis or 
the female to male ratio during the two time periods 
(p  >  0.05). In regard to tumor characteristics, multifo-
cality and N-EFVC was more often present while classic 
PTMC was less common in patients in the TP2, com-
pared to patients in the TP1 (p =  0.007, p  <  0.001 and 
p = 0.043 respectively).
The prevalence of incidental PTMC was high but simi-
lar in the two time periods (84.6 vs 80 %, p = 0.286). The 
majority of patients in TP2 underwent a total or near 
total thyroidectomy compared to patients in TP1 (91.7 
vs 80 %, p = 0.001). However, more patients underwent 
thyroidectomy for toxic multinodular disease and less for 
Graves’ disease during TP1 compared to patients in the 
TP2 (p = 0.02 and 0.043 respectively).
A significant percentage of patients underwent adju-
vant radioiodine ablation, yet no difference was found 
between the two time periods (73.8 vs 79.5 %, p = 0.228). 
The rate of persistence was very low and not significant 
(3.1 vs 6.6  %, p  =  0.165), while disease recurrence was 
observed in only 2 (0.6 %) patients, one from each time 
period.
Comparison between incidental and non‑incidental PTMCs
The clinical and histopathological characteristics of 
patients with incidental and non-incidental PTMCs are 
presented in Table 3.
Mean age at diagnosis was similar for patients with 
incidental and non-incidental PTMCs. There was a sta-
tistically significant higher proportion of women in the 
cases of incidental PTMCs (82.5 vs 62.3  %, p  <  0.001). 
The prevalence of hyperthyroidism at diagnosis was 
higher in patients of the incidental PTMCs group (20.2 vs 
0 %, p = <000.1) as none of the patients who underwent 
FNA or had positive lymph nodes had hyperthyroidism. 
Hashimoto thyroiditis was present at similar percent-
ages in the two groups. Family history was positive at the 
same low percentages in both groups. The proportion 
of patients presenting with a single nodule was statisti-
cally significantly higher in the group of patients with 
non-incidental PTMCs, while the patients who under-
went surgery for other pathology non-related to thyroid 
malignancy had multinodular disease at higher propor-
tion (p = 0.047).
Unifocal disease as well as the size of the focus did not 
differ between patients with incidental and non-inci-
dental PTMCs. Loco-regional extension and/or lymph-
node involvement (T > 1 and/or N > 0) were detected in 
a statistically significantly higher percentage in patients 
with non-incidental PTMCs (6.2 % vs 31.1 %, p < 0.001). 
Capsule involvement was also present in a much higher 
proportion in the group of non-incidental PTMCs (7.7 
vs 77  %, p  <  0.001). As far as the histological subtypes 
of PTMC are concerned we found a significantly higher 
frequency of the N-EFVC subtype in patients from the 
group of non-incidental PTMCs (13.1 vs 36 %, p < 0.001). 
We did not find any other differences regarding the rest 
histological subtypes.
The type of surgery did not differ between the two 
groups of patients. However, a statistically significantly 
higher proportion of patients with non-incidental 
PTMCS underwent adjuvant radioiodine ablation (73.7 
vs 93.4  %, p  <  0.001). Disease recurrence was observed 
in two patients with incidental PTMCs. Persistent dis-
ease was more frequent in patients with non-incidental 
PTMCs but without achieving statistical significance (3 
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vs 8.2  %, p =  0.054). The vast majority of patients with 
incidental and non-incidental PTMCs were disease free 
without any statistically significant difference (96.3 vs 
91.8 %, p = 0.120).
Discussion
In the present study we confirmed the benign course of 
PTMC after a detailed and extensive follow-up period 
ranging from 5 up to 33 years. Only a minute proportion 
of patients (0.6  %) presented with a recurrence. How-
ever, a small percentage (3.9 %) of patients had persistent 
disease more frequently in those with non-incidental 
PTMCs but without achieving statistical significance. In 
this cohort we did not find any remarkable differences in 
the presentation, clinical characteristics, histology and 
outcome of the most recently detected cases compared 
to those detected in previous decades. Also we did not 
find any significant difference in persistence or recur-
rence between the radioiodine ablated and non-ablated 
patients.
Our results are in agreement with most studies, which 
showed that PTMCs have excellent prognosis with a 
mortality of about 1 % and recurrence or persistence of 
only 1.4–10.5  % [12, 21–29]. Furthermore the study by 
Ito et al. [30] who prospectively followed up a large group 
of patients with PTMCs without any intervention did not 
show poorer prognosis for these patients. The findings of 
our study gain importance in the light of the detailed and 
Table 2 Comparison of the clinical and histopathological characteristics between the time periods 1982–2000 and 2001–
2010
1982–2000 2001–2010 P value
Number of patients 130 205
Age at diagnosis 47.8 ± 11.8 (range 20–73) years 49.2 ± 13.1 (range 16–81) years 0.321
Gender 108F (83.1 %) 156F (76.1 %) 0.128
22 M (16.9 %) 49 M (23.9 %)
Hyperthyroidism 24/130 (19.2 %) 22/205 (10.2 %) 0.033
Graves 7/24 (32 %) 14/22 (61.9 %) 0.019
Toxic Adenoma 4/24 (16.6 %) 2/22 (9.1 %) 0.370
Toxic MNG 13/24 (54.2 %) 6/22 (27.3 %) 0.064
Hashimoto 15/130 (11.5 %) 32/205 (15.6 %) 0.296
Family history 3/130 (2.3 %) 2/205 (1 %) 0.327
Singlenodular 37/130 (28.5 %) 50/205 (24.4 %) 0.408
Multinodular 93/130 (71.5 %) 155/205 (75.6 %)
Incidental 110/130 (84.6 %) 164/205 (80 %) 0.286
Non-incidental 20/130 (15.4 %) 41/205 (20 %)
Unifocal 95/130 (73.1 %) 120/205 (58.5 %) 0.007
Multifocal 35/130 (26.9 %) 85/205 (41.5 %)
< or = 5 mm 46/95 (48.4 %) 63/120 (52.5 %) 0.552
>5 mm (of unifocal cases) 49/95 (51.6 %) 57/120 (47.5 %)
Metastases 0/130 (0 %) 0/205 (0 %) >0.999
Capsule involvement 23/130 (17.7 %) 45/205 (22 %) 0.345
T > 1 and/or N > 0 15/130 (11.5 %) 21/205 (10.2 %) 0.709
Histological types 75/130 (57.7 %) CPC 95/205 (46.3 %) 0.043
25/130 (19.2 %) EFVC 36/205 (17.6 %) 0.699
11/130 (8.5 %) N-EFVC 47/205 (22.9 %) <0.001
17/130 (13.1 %) SVC 24/205 (11.7 %) 0.709
2/130 (1.5 %) T-CVC 3/205 (1.5 %) 0.956
Total or near total thyroidectomy 104/130 (80 %) 188/205 (91.7 %) 0.001
131I 96/130 (73.8 %) 163/205 (79.5 %) 0.228
Follow up 13.9 ± 6.6 (range 5–33) years 8.5 ± 2.7 (range 5–14) years <0.001
Recurrence 1/130 (0.8 %) 1/205 (0.5 %) 0.745
Persistence 3/130 (2.3 %) 10/205 (4.9 %) 0.235
Disease free 126/130 (96.9 %) 194/205 (94.6 %) 0.324
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extensive follow-up from 5 to 33 years. Furthermore the 
lack of differences in persistence or recurrence between 
the radioiodine ablated and non-ablated is in agreement 
with previous studies [12, 22–30] and recent guidelines 
that suggest no need for completion thyroidectomies, 
lymph node dissections, radioiodine ablation and sup-
pressive thyroxine treatment for PTMCs [10, 11, 31].
Nevertheless, the potential aggressiveness of PTMCs 
demonstrated by some studies [12–18] has raised the 
question of identifying possible risk factors for mortal-
ity and recurrence, which could help clinicians in decid-
ing which patients need to be treated as if they had any 
other worrisome papillary thyroid carcinoma. These fac-
tors are described to be mostly the size of the tumor, the 
capsule involvement and invasiveness, the presence of 
lymph node metastases and multifocality [32, 33]. Sev-
eral studies have reported risk factors for recurrence that 
have not been confirmed in other series. This variation is 
not surprising if we just think of the very low recurrence 
percentages. Any result found in such low recurrence 
rates can be explained by the biases that may be present 
in every retrospective cohort study [33, 34]. We can-
not claim that we confirmed indeed such factors or can 
propose any new ones. Indeed, the percent of tall-cell 
variant—which is thought to exhibit more aggressive 
pathologic characteristics than classic PTMCs- in our 
cohort was 1.5 %. All of them underwent total thyroidec-
tomy and thyroid remnant ablation and no one had per-
sistence or recurrence during follow-up. Of the thirteen 
patients with persistent disease, five of them had lymph 
nodes (4 CPC, 1 SVC), capsule involvement was present 
in three, while one of them was T > 1 and five of them 
N > 0. Therefore, we cannot conclude any effect of sub-
type, lymph node metastases or capsule involvement on 
outcome. The percentage of patients with persistent dis-
ease—small but not negligible—underscores the need for 
close follow up in all PTMC patients.
No change was noted in the mean age at diagnosis or 
the female to male ratio during the two time periods of 
the study. Furthermore, we did not find any remarkable 
Table 3 Comparison of the clinical and histopathological characteristics between incidental and non-incidental PTMCs
Incidental PTMCs Non‑incidental PTMCs P value
Number of patients 274 61
Age at diagnosis 49.1 ± 12.5 (range 16 – 76) years 47.9 ± 13.1 (range 18–81) years 0.485
Gender 226F (82.5 %) 38F (62.3 %) <0.001
48 M (17.5 %) 23 M (37.7 %)
Hyperthyroidism 46/228 (20.2 %) 0/61 (0 %) <0.001
Graves 21/46 (45.7 %) 0/0 –
Hashimoto 42/274 (15.3 %) 5/61 (8.2 %) 0.147
Family History 4/274 (1.5 %) 1/61 (1.6 %) 0.917
Singlenodular 65/274 (23.7 %) 22/61 (36.1 %) 0.047
Multinodular 209/274 (76.3 %) 39/61 (63.9 %)
Unifocal 179/274 (65.3 %) 36/61 (59 %) 0.352
Multifocal 95/274 (34.7 %) 25/61 (40.1 %)
< or = 5 mm 96/179(53.6 %) 13/36 (36.1 %) 0.055
> 5 mm (of unifocal cases) 83/179 (46.4 %) 23/36 (63.9 %)
Metastases 0/274 (0 %) 0/61 (0 %) >0.999
Capsule involvement 21/274 (7.7 %) 47/61 (77 %) <0.001
T > 1 and/or N > 0 17/274 (6.2 %) 19/61 (31.1 %) <0.001
Histological types 145/274 (52.9 %) CPC 25/61 (41 %) 0.091
53/274 (19.4 %) EFVC 8/61 (13.1 %) 0.254
36/274 (13.1 %) N-EFVC 22/61 (36 %) <0.001
37/274 (13.5 %) SVC 4/61 (6.6 %) 0.134
3/274 (1.1 %) T-CVC 2/61 (3.3 %) 0.203
Total or near total thyroidectomy 240/274 (87.5 %) 52/61 (85.2 %) 0.620
131I 202/274 (73.7 %) 57/61 (93.4 %) <0.001
Follow up 10.9 ± 5.4 (range 5–33) years 9.1 ± 4.3 (range 5–27.5) years 0.005
Recurrence 2/274 (0.7 %) 0/61 (0 %) 0.503
Persistence 8/274 (3 %) 5/61 (8.2 %) 0.054
Disease free 264/274 (96.3 %) 56/61 (91.8 %) 0.120
Page 7 of 9Vlassopoulou et al. BMC Res Notes  (2016) 9:252 
differences in the presentation, clinical characteristics, 
histology and outcome of the most recently detected 
cases compared to those detected in previous decades. 
In regard to PTMC subtypes, there was a decrease in the 
percentage of the CPC and an increase in the percentage 
of N-EFVC during the latest study period. This finding is 
in agreement with a recent study from US where these 
changes in tumor histology after 2000 were accompanied 
by an increase in BRAF and RAS mutations, suggesting 
new etiologic factors [35]. Furthermore, multifocality was 
more often present in patients in the TP2. This may be 
due to the application of better and more sophisticated 
pathology techniques. Overall the character of the dis-
ease does not seem to have changed remarkably during 
these 30  years in Greece, despite the change from an 
iodine-deficient to an iodine-sufficient status [4].
In our series 81.8 % of the patients were diagnosed with 
PTMC undergoing thyroidectomy for non-malignant 
thyroid disease which is in agreement with previous 
studies in Greece that reported an even higher relative 
frequency of incidentally discovered PTMCs (88 %) [21, 
36]. Prevalence of incidental PTMC was high but simi-
lar in the two time periods. Three decades ago, an inci-
dence of 1 % was reported for incidental PTMCs [21] and 
increased about seven times in a more recent study [37]. 
This may be partly related to broader application of total 
or near total thyroidectomy in recent decades and it was 
reconfirmed in our study. Many other studies from other 
countries as well support that PTMCs are mostly inci-
dental findings in surgeries for other pathologies non-
related to thyroid malignancy [38, 39].
A recent meta-analysis [40] which included 3523 sub-
jects (854 patients with incidental PTMC and 2669 
patients with non-incidental PTMC) with mean follow-
up of 70 months showed that non-incidental PTMC has 
different clinical characteristics (larger tumor size, higher 
incidence of lymph node metastases) and a much higher 
recurrence rate than incidental PTMCs (OR = 14.7, 95 % 
CI 5.6–54.8, p < 0.001). We have to mention the signifi-
cant heterogeneity detected for all parameters especially 
in the non-incidental group. But even after exclud-
ing two studies to improve heterogeneity, recurrence 
rate remained much higher for non-incidental PTMCs 
(OR  =  9.2, 95  % CI 3.5–34.42, p  <  0.001) [39]. In our 
cohort patients with non-incidental PTMCs presented 
in statistically significantly higher percentages with a 
single nodule, loco-regional extension and/or lymph-
node, capsule involvement and had higher frequency of 
the invasive subtype. In a significantly higher proportion, 
patients with non-incidental PTMCS underwent adju-
vant radioiodine ablation. Nevertheless disease recur-
rence was observed in patients with incidental PTMCs, 
while persistent disease was more frequent in patients 
with non-incidental PTMCs but without achieving statis-
tical significance.
In our study an important number of patients pre-
sented with hyperthyroidism. Specifically, more patients 
underwent thyroidectomy for toxic multinodular dis-
ease and less for Graves’ disease during time period 1 
compared to patients in the time period 2. This could 
be explained as patients with symptoms seek for medi-
cal help visit doctors earlier. Another possible reason 
may be that these patients were more likely to undergo 
surgery especially in patients with Graves’ disease and 
recurrence or coexisting with single nodules. Despite the 
reported more aggressive course of PTC in Graves’, this 
was not the case for PMTC in our cohort [41–43]. Hashi-
moto’s thyroiditis was also present at a high percentage in 
patients with PTMCs in agreement with previous studies 
[20, 41–43]. Patients with Hashimoto’s are more closely 
followed up and this can explain the fact that the rate of 
detection of PTCs in general may be 1.5–2 times higher 
in these patients [21].
The advantages of our study are the large number of 
patients, the common origin of the patients and mainly 
the long term and detailed follow up. To our knowledge, 
this is the first study where patients were followed for at 
least 5 years and a mean of 10.6 years. Nevertheless the 
very low recurrence rate in our cohort, underscores the 
need for even larger sample sizes in order to ensure this 
non-aggressive behavior of PTMCs and justify a more 
conservative approach.
In conclusion, PTMCs appear to have a benign course 
in the majority of patients initially treated with total or 
near-total thyroidectomy without differences in recur-
rence or persistence between the radioiodine ablated 
and non-ablated patients. We did not note any important 
changes regarding clinical presentation, tumor charac-
teristics, recurrence or persistence of PTMCs during the 
last three decades.
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